Vertex misses quarterly results on weaker-than-expected demand for cystic fibrosis drug
Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday, due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta.
More info
